These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9843458)

  • 21. A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the Central Illinois Thrombolytic Therapy Study).
    Taylor GJ; Moses HW; Koester D; Colliver JA; Katholi RE; Dove JT; Woodruff RC; Mikell FL; Becker LC; Sheehan FH
    Am J Cardiol; 1993 Nov; 72(14):1010-4. PubMed ID: 8213579
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.
    Bode C; Smalling RW; Berg G; Burnett C; Lorch G; Kalbfleisch JM; Chernoff R; Christie LG; Feldman RL; Seals AA; Weaver WD
    Circulation; 1996 Sep; 94(5):891-8. PubMed ID: 8790022
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increase in thrombin generation after coronary thrombolysis with rt-PA or streptokinase with simultaneous heparin versus heparin alone.
    Réganon E; Ferrando F; Vila V; Villa P; Martínez-Sales V; Fayos L; Ruano M; Aznar J
    Haemostasis; 1998; 28(2):99-105. PubMed ID: 10087435
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [t-PA in thrombolytic therapy of acute myocardial infarct].
    Rutsch W; Schmutzler H
    Herz; 1994 Dec; 19(6):336-52. PubMed ID: 7843690
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin.
    Leebeek FW; Kluft C; Knot EA; Los P; Cohen AF; Six AJ
    J Am Coll Cardiol; 1990 May; 15(6):1212-20. PubMed ID: 1691750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reactive coagulation induced by plasmin in patients treated with recombinant tissue-type plasminogen activator.
    Gram J; Munkvad S; Leebeek FW; Kluft C; Jespersen J
    Coron Artery Dis; 1993 Apr; 4(4):371-7. PubMed ID: 8261210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of thrombolytic therapy on parameters of endothelial function in patients with myocardial infarction].
    Barbarash OL; Kashtalap VV; Voroncova NL; Suslova TE; Karetnikova VN; Barbarash LS
    Kardiologiia; 2007; 47(10):54-8. PubMed ID: 18260945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New developments in thrombolytic therapy.
    Collen D; Gold HK
    Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Failure of fixed dose intravenous heparin to suppress increases in thrombin activity after coronary thrombolysis with streptokinase.
    Galvani M; Abendschein DR; Ferrini D; Ottani F; Rusticali F; Eisenberg PR
    J Am Coll Cardiol; 1994 Nov; 24(6):1445-52. PubMed ID: 7930274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
    GUSTO investigators
    N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation and comparison of the adverse effects of streptokinase and alteplase.
    Tisdale JE; Colucci RD; Ujhelyi MR; Kluger J; Fieldman A; Chow MS
    Pharmacotherapy; 1992; 12(6):440-4. PubMed ID: 1492007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Streptokinase versus alteplase: comparison of echocardiographic parameters and post-coronarography treatment--our experience.
    Resic N; Durak-Nalbantic A; Dzubur A; Hodzic E; Kulic M; Sabanovic-Bajramovic N; Jahic E
    Med Arch; 2013; 67(5):322-5. PubMed ID: 24601161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review.
    Dundar Y; Hill R; Dickson R; Walley T
    QJM; 2003 Feb; 96(2):103-13. PubMed ID: 12589008
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Coronary flow and hemorrhagic complications after alteplase and streptokinase administration in patients with acute myocardial infarction].
    Kostić T; Perisić Z; Milić D; Apostolović S; Martinović SS; Bozinović N; Mitov V; Vidanović M
    Vojnosanit Pregl; 2009 Mar; 66(3):218-22. PubMed ID: 19341228
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics.
    Lancet; 1995 Aug; 346(8971):329-36. PubMed ID: 7623530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator.
    Peuhkurinen K; Risteli L; Jounela A; Risteli J
    Am Heart J; 1996 Jan; 131(1):7-13. PubMed ID: 8554022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrinogen breakdown, long-lasting systemic fibrinolysis, and procoagulant activation during alteplase double-bolus regimen in acute myocardial infarction.
    Stangl K; Laule M; Tenckhoff B; Stangl V; Gliech V; Dübel P; Grohmann A; Melzer C; Langel J; Wernecke KD; Baumann G; Ziemer S
    Am J Cardiol; 1998 Apr; 81(7):841-7. PubMed ID: 9555772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase.
    Gomaraschi M; Ossoli A; Vitali C; Pozzi S; Vitali Serdoz L; Pitzorno C; Sinagra G; Franceschini G; Calabresi L
    Biochem Pharmacol; 2013 Feb; 85(4):525-30. PubMed ID: 23219857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of thrombolysis with alteplase (50 mg) plus tirofiban versus alteplase (100 mg) alone in acute myocardial infarction: preliminary findings.
    Sarullo FM; Pasquale PD; D'Alfonso G; Amerigo L; Cannizzaro S; Castello A
    Ital Heart J; 2001 Aug; 2(8):605-11. PubMed ID: 11577835
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tenecteplase: a review of its pharmacology and therapeutic efficacy in patients with acute myocardial infarction.
    Dunn CJ; Goa KL
    Am J Cardiovasc Drugs; 2001; 1(1):51-66. PubMed ID: 14728052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.